Perirenal Fats of Chronic Kidney Disease in Patients With Fatty Liver Disease.
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University
About this trial
Exploring the association of perirenal fat thickness assessed by MRI in CKD patients with FLD.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age more than 18 years old regardless of gender
Disqualifiers
Other causes of chronic liver diseases (HCV, HBV...).
End stage renal diseases (GFR<15 ml/min).
A history of significant alcohol intake (>20 g/day in females and 30 g/day in males).
Those using medications that can cause fatty liver.
Trial population
Patients will be recruited from the out-patient clinics of the Internal Medicine Department, Assiut university
Trial design
Design model
Other
Time perspective
Cross-sectional
Treatments tested in this trial
MRI
DeviceMagnetic Resonance Imaging (MRI) is a non-invasive imaging technology that produces three dimensional detailed anatomical images. Patients will be subjected to MRI scans and imaging of the kidneys and liver
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Incidence of increase perirenal fat thickness in CKD patients with fatty liver disease. Perirenal fat thickness measured by magnetic resonance imaging (MRI) and pelvic abdominal ultrasound (PAUS).
Correlation between perirenal fat thickness measured by MRI and PAUS and the main markers of kidney function, such as estimated glomerular filtration rate (eGFR), albuminuria and serum urate in CKD patient with FLD.
Time frame
BaselineLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: